Image-defined Risk Factors Associated with MYCN Oncogene Amplification in Neuroblastoma and Their Association with Overall Survival

Overview

Journal Abdom Radiol (NY)

Publisher Springer

Specialties Gastroenterology
Radiology

Date 2024 Mar 4

PMID 38436700

Authors

Haoru Wang

Ting Li

Xiaoying Ni

Xin Chen

Ling He

Jinhua Cai

Affiliations

Soon will be listed here.

Abstract

Objective: The MYCN oncogene is a critical factor in the development and progression of neuroblastoma, and image-defined risk factors (IDRFs) are radiological findings used for the preoperative staging of neuroblastoma. This study aimed to investigate the specific categories of IDRFs associated with MYCN amplification in neuroblastoma and their association with overall survival.

Method: A retrospective analysis was conducted on a cohort of 280 pediatric patients diagnosed with neuroblastoma, utilizing a combination of clinical and radiological data. MYCN amplification status was ascertained through molecular testing, and the assessment of IDRFs was conducted using either contrast-enhanced computed tomography or magnetic resonance imaging. The specific categories of IDRFs associated with MYCN amplification and their association with overall survival were analyzed.

Results: MYCN amplification was identified in 19.6% (55/280) of patients, with the majority of primary lesions located in the abdomen (53/55, 96.4%). Lesions accompanied by MYCN amplification exhibited significantly larger tumor volume and a greater number of IDRFs compared with those without MYCN amplification (P < 0.001). Both univariate and multivariate analyses revealed that coeliac axis/superior mesenteric artery encasement and infiltration of adjacent organs/structures were independently associated with MYCN amplification in abdominal neuroblastoma (P < 0.05). Patients presenting with more than four IDRFs experienced a worse prognosis (P = 0.017), and infiltration of adjacent organs/structures independently correlated with overall survival in abdominal neuroblastoma (P = 0.009).

Conclusion: The IDRFs are closely correlated with the MYCN amplification status and overall survival in neuroblastoma.

Citing Articles

Stratification of Anatomical Imaging Features Between High-Risk and Non-High-Risk Groups in Neuroblastoma.

Wang H, Chen X, He L, Cai J Cancer Control. 2025; 32():10732748251315883.

PMID: 39833998 PMC: 11748161. DOI: 10.1177/10732748251315883.

Quantitative MRI in Childhood Neuroblastoma: Beyond the Assessment of Image-defined Risk Factors.

Wang H, Cai J Radiol Imaging Cancer. 2024; 6(6):e240089.

PMID: 39485111 PMC: 11615636. DOI: 10.1148/rycan.240089.

Inter-observer variability in assessing image-defined risk factors: implications for risk stratification in locoregional abdominopelvic neuroblastoma.

Wang H, Chen M, He L, Chen X Abdom Radiol (NY). 2024; .

PMID: 39467915 DOI: 10.1007/s00261-024-04647-4.

References

Colon N, Chung D . Neuroblastoma. Adv Pediatr. 2011; 58(1):297-311. PMC: 3668791. DOI: 10.1016/j.yapd.2011.03.011. View

Katta S, Nagati V, Paturi A, Murakonda S, Murakonda A, Pandey M . Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets. J Control Release. 2023; 357:444-459. DOI: 10.1016/j.jconrel.2023.04.001. View

Kholodenko I, Kalinovsky D, Doronin I, Deyev S, Kholodenko R . Neuroblastoma Origin and Therapeutic Targets for Immunotherapy. J Immunol Res. 2018; 2018:7394268. PMC: 6079467. DOI: 10.1155/2018/7394268. View

Tolbert V, Matthay K . Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018; 372(2):195-209. PMC: 5918153. DOI: 10.1007/s00441-018-2821-2. View

Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M . Molecular Genetics in Neuroblastoma Prognosis. Children (Basel). 2021; 8(6). PMC: 8226597. DOI: 10.3390/children8060456. View

Otte J, Dyberg C, Pepich A, Johnsen J . MYCN Function in Neuroblastoma Development. Front Oncol. 2021; 10:624079. PMC: 7873735. DOI: 10.3389/fonc.2020.624079. View

Zimmerman M, Liu Y, He S, Durbin A, Abraham B, Easton J . Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov. 2017; 8(3):320-335. PMC: 5856009. DOI: 10.1158/2159-8290.CD-17-0993. View

Bhavsar S . Metastasis in neuroblastoma: the question. Front Oncol. 2023; 13:1196861. PMC: 10233040. DOI: 10.3389/fonc.2023.1196861. View

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

10.

Chen A, Trout A, Towbin A . A review of neuroblastoma image-defined risk factors on magnetic resonance imaging. Pediatr Radiol. 2018; 48(9):1337-1347. DOI: 10.1007/s00247-018-4117-9. View

11.

Laura B, Radu B, Patricia C, Andreea M . Association of Image-Defined Risk Factors with Clinical, Biological Features and Outcome in Neuroblastoma. Children (Basel). 2022; 9(11). PMC: 9688519. DOI: 10.3390/children9111707. View

12.

Brisse H, Blanc T, Schleiermacher G, Mosseri V, Philippe-Chomette P, Janoueix-Lerosey I . Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PLoS One. 2017; 12(9):e0185190. PMC: 5612658. DOI: 10.1371/journal.pone.0185190. View

13.

Temple W, Vo K, Matthay K, Balliu B, Coleman C, Michlitsch J . Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. Cancer Med. 2020; 10(7):2232-2241. PMC: 7982630. DOI: 10.1002/cam4.3663. View

14.

Brisse H, McCarville M, Granata C, Krug K, Wootton-Gorges S, Kanegawa K . Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011; 261(1):243-57. DOI: 10.1148/radiol.11101352. View

15.

Vo K, Matthay K, Neuhaus J, London W, Hero B, Ambros P . Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014; 32(28):3169-76. PMC: 4171360. DOI: 10.1200/JCO.2014.56.1621. View

16.

Oldridge D, Truong B, Russ D, Dubois S, Vaksman Z, Mosse Y . Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma. J Natl Cancer Inst. 2019; 111(11):1192-1201. PMC: 6855946. DOI: 10.1093/jnci/djz027. View

17.

Ruiz-Perez M, Henley A, Arsenian-Henriksson M . The MYCN Protein in Health and Disease. Genes (Basel). 2017; 8(4). PMC: 5406860. DOI: 10.3390/genes8040113. View

18.

Phelps H, Ndolo J, Van Arendonk K, Chen H, Dietrich H, Watson K . Association between image-defined risk factors and neuroblastoma outcomes. J Pediatr Surg. 2019; 54(6):1184-1191. PMC: 6628713. DOI: 10.1016/j.jpedsurg.2019.02.040. View

19.

Tan E, Merchant K, Kn B, Cs A, Zhao J, Saffari S . CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma. Childs Nerv Syst. 2022; 38(8):1487-1495. DOI: 10.1007/s00381-022-05534-3. View

20.

Wang H, Li T, Chen X, Zhu J, Xie M, Zhang L . Correlations Between Preoperative Radiographic Vascular Involvement of Abdominal/Pelvic Neuroblastomas on Computed Tomography and Intraoperative Vascular Injuries: Experience From a Tertiary Children's Hospital. Acad Radiol. 2022; 30(7):1350-1357. DOI: 10.1016/j.acra.2022.09.010. View